Chirality and pharmacokinetics: an area of neglected dimensionality?
about
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategyStereoselective property of 20(S)-protopanaxadiol ocotillol type epimers affects its absorption and also the inhibition of P-glycoproteinUsing biological performance similarity to inform disaccharide library design.Chiral analytical method development of liquiritigenin with application to a pharmacokinetic studyChiral analytical method development and application to pre-clinical pharmacokinetics of pinocembrin.Pharmacologically active compounds in the environment and their chirality.Chemodiversity and molecular plasticity: recognition processes as explored by property spaces.Chirality and anaesthetic drugs: A review and an update.Isolation and evaluation of the enantiospecific antitubercular activity of a novel triazole compound.Transcriptome-enabled discovery and functional characterization of enzymes related to (2S)-pinocembrin biosynthesis from Ornithogalum caudatum and their application for metabolic engineeringCharacterizing QT interval prolongation in early clinical development: a case study with methadone.Synthesis, molecular modeling, and biological evaluation of novel chiral thiosemicarbazone derivatives as potent anticancer agents.Pharmacokinetics of nateglinide enantiomers and their metabolites in Goto-Kakizaki rats, a model for type 2 diabetes mellitus.A clinical and microbiological study on the enantiomers of delmopinol.Stereoselective formation and metabolism of 20(S)-protopanaxadiol ocotillol type epimers in vivo and in vitro.Reliable HPLC separation, vibrational circular dichroism spectra, and absolute configurations of isoborneol enantiomers.Bifunctional catalysis in the stereocontrolled synthesis of tetrahydro-1,2-oxazines.Pharmacokinetic comparisons of S-oxiracetam and R-oxiracetam in beagle dogs.
P2860
Q27682798-726C50BB-8787-49C6-BCC9-7AA63C4074DAQ28539251-0EC2C7EB-1FA7-4C0A-AF11-785495C4AB85Q33419659-A7EE14CC-4745-4B14-82F7-4B681F6B1CADQ34344435-70A83844-808B-4766-A591-8B780984E3B1Q34501465-EFCBDB03-C529-41F2-9928-225EFE0C452FQ37790280-C6BDDFDA-8A34-4D6B-8442-24F28127417AQ37894716-15BB70CB-57E0-4D66-9763-332A3690FBBDQ37973723-C6BB4293-FE0F-4AAF-80EB-069E95107C11Q38258997-E10E4A3F-FC07-4058-878E-9AA752666737Q38267550-BEAEB5D2-EAE5-444D-9F79-AF2B908DCD3FQ38735144-DE37FC6C-85F2-4E33-BE3E-39B825307FACQ38940208-E2CB7CAC-6EA3-4634-8F68-3A0063A2D67AQ46039814-8C55F950-9A10-4EB2-AF95-F962FFCB0D1EQ46585672-1A7C1D32-29D9-4147-AE5C-816CD53C8CFDQ46810771-43E42737-2529-4D2F-917D-154CC46187BFQ47921256-432DD9EB-8239-4E3D-AADE-9E99372380B2Q49626810-352950CF-DDC4-4BCB-8EDA-E77EFBD6BB8CQ53084296-24658DEF-3E2E-4F1C-8A82-D8CDC6C22175
P2860
Chirality and pharmacokinetics: an area of neglected dimensionality?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Chirality and pharmacokinetics: an area of neglected dimensionality?
@en
type
label
Chirality and pharmacokinetics: an area of neglected dimensionality?
@en
prefLabel
Chirality and pharmacokinetics: an area of neglected dimensionality?
@en
P2860
P1476
Chirality and pharmacokinetics: an area of neglected dimensionality?
@en
P2093
Andrew J Hutt
P2860
P304
P356
10.1515/DMDI.2007.22.2-3.79
P577
2007-01-01T00:00:00Z